PBK, PDZ binding kinase, 55872

N. diseases: 121; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0017638
Disease: Glioma
Glioma
0.060 Biomarker disease BEFREE In this study, we administered an anti-glioma/GSC drug temozolomide (TMZ) and OTS964, an inhibitor for T-Lak cell originated protein kinase, in combination (T&O), investigating whether together they efficiently and substantially shrink the initial size of power-law coded GSC populations and slow the long-term re-growth of drug-resistant GSC populations. 31040930 2019
CUI: C0017638
Disease: Glioma
Glioma
0.060 Biomarker disease BEFREE TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ. 31378785 2019
CUI: C0017638
Disease: Glioma
Glioma
0.060 AlteredExpression disease BEFREE TOPK protein level and TOPK mRNA and protein levels in six glioma cell lines were examined using Western blot and reverse transcription-polymerase chain reaction (RT-PCR), respectively. 29271010 2018
CUI: C0017638
Disease: Glioma
Glioma
0.060 Biomarker disease BEFREE This study addressed whether a novel anti-cancer drug, OTS964, an inhibitor for T-LAK cell originated protein kinase (TOPK), is effective in reducing the size of the heterogeneous GSC populations, a power-law coded heterogeneous GSC populations consisting of glioma sphere (GS) clones, by detailing quantitative growth properties. 29423027 2018
CUI: C0017638
Disease: Glioma
Glioma
0.060 AlteredExpression disease BEFREE The serine/threonine-protein kinase PFTAIRE 1 (PFTK1) is a member of the cyclin‑dependent kinase family that is highly expressed in several malignant tumors, including hepatocellular carcinoma, esophageal, breast and gastric cancers, and glioma. 28498444 2017
CUI: C0017638
Disease: Glioma
Glioma
0.060 Biomarker disease BEFREE Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo. 26081429 2015